Shanghai – September 25, 2026 -- IASO Biotechnology reported an 88.9% objective response rate for its dual-targeted CAR-T therapy RD140 in a first-in-human Phase 1 trial of nine heavily pretreated multiple myeloma and plasma cell leukemia patients, with the response rate reaching 100% in the higher-dose cohort.
RD140 achieves 88.9% MRD negativity in high-risk relapsed patients
The investigator-initiated trial (NCT06655519), led by Professor Jin Lu of Peking University People's Hospital, enrolled patients who had failed at least three prior lines of therapy, including two who had previously received BCMA-targeted treatment. All nine patients were triple-class exposed, and six were penta-exposed. As of the May 6, 2026 data cutoff, with a median follow-up of 6.05 months, 88.9% of patients achieved MRD negativity at the 10−5 threshold, with six reaching this benchmark as early as day 28. Median progression-free survival has not been reached.
No neurotoxicity observed across two dose levels
Patients received a single RD140 infusion following three days of lymphodepletion with cyclophosphamide and fludarabine, at doses of 1×105 cells/kg (three patients) or 3×105 cells/kg (six patients). Cytokine release syndrome occurred in all nine patients but was predominantly low-grade -- eight cases were grade 1-2 and one was grade 3, with a median onset of four days and median duration of 5.3 days. No neurotoxicity, including immune effector cell-associated neurotoxicity syndrome, was reported at any grade.
FasT CAR-T platform cuts manufacturing time to three to four days
RD140 is built on IASO Bio's FasT CAR-T rapid manufacturing platform, which the company said completes cell production in three to four days. Pharmacokinetic data showed a median time to peak cell expansion of 15 days and a median peak CAR transgene copy number of 112,981.7 copies per microgram of DNA; soluble BCMA levels dropped below detectable limits in all nine patients post-infusion.
Jin said the dual BCMA/GPRC5D targeting design delivered deep responses without ICANS in a population that was mostly penta-drug exposed and high-risk, adding that the rapid manufacturing window could benefit more critically ill patients.
The data were presented as a poster discussion (Abstract PA-200) at the 2026 International Myeloma Society Annual Meeting.